Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

446
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
446
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

491
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
491
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Patient Perspectives on Cardiac Gene Therapy: A Survey of Knowledge, Attitudes, and Educational Needs.

Journal of cardiac failure·2026
Same author

Cardiology Provider Knowledge and Attitudes Toward Cardiac Gene Therapy: A Multi-Institutional National Survey.

JACC. Heart failure·2026
Same author

Angiotensin-Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure.

Journal of the American Heart Association·2026
Same author

Finerenone and polypharmacy in heart failure with mildly reduced or preserved ejection fraction: a marker of risk, not a barrier to therapy.

European journal of heart failure·2026
Same author

Health status trajectories using Markov modeling in patients with heart failure with preserved ejection fraction.

Revista espanola de cardiologia (English ed.)·2026
Same journal

Artificial Intelligence in Echocardiography for Valvular Heart Disease.

Trends in cardiovascular medicine·2026
Same journal

Inflammation as a Fulcrum in Cardiovascular Disease: The Evolving Case for High-Sensitivity C-Reactive Protein.

Trends in cardiovascular medicine·2026
Same journal

Comment on "advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation".

Trends in cardiovascular medicine·2026
Same journal

Response to: Comment on "Advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation" (TCM-D-26-00198).

Trends in cardiovascular medicine·2026
Same journal

High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure - a review.

Trends in cardiovascular medicine·2026
Same journal

The cost of false dichotomies in a dynamic disease.

Trends in cardiovascular medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Gene therapy for heart failure.

Barry Greenberg1

  • 1University of California, San Diego, La Jolla, CA, USA.

Trends in Cardiovascular Medicine
|January 9, 2017
PubMed
Summary
This summary is machine-generated.

Gene transfer offers promising new strategies for heart failure treatment, but clinical application faces significant hurdles. Further research is crucial to overcome obstacles and realize the full potential of this innovative therapy.

Keywords:
Adeno-associated virusGene therapyHeart failureSERCA2a

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.3K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.3K

Related Experiment Videos

Last Updated: Mar 9, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.3K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.3K

Area of Science:

  • Cardiovascular Medicine
  • Molecular Therapy
  • Biotechnology

Background:

  • Heart failure (HF) affects a growing population with significant morbidity and mortality.
  • Current drug and device therapies have limitations in improving quality of life and survival.
  • Understanding HF mechanisms reveals targets for novel gene transfer therapies.

Purpose of the Study:

  • To review gene transfer as a therapeutic strategy for heart failure.
  • To identify critical factors for successful clinical translation of gene transfer.
  • To discuss recent clinical studies and future directions.

Main Methods:

  • Review of existing literature on gene transfer for heart failure.
  • Analysis of experimental models and early-phase clinical trials.
  • Discussion of challenges and opportunities in gene therapy development.

Main Results:

  • Gene transfer has shown promise in preclinical heart failure models.
  • Early clinical studies in heart failure patients are emerging.
  • Several factors, including delivery and safety, need optimization for clinical success.

Conclusions:

  • Gene transfer holds significant promise for treating heart failure.
  • Overcoming translational obstacles is essential for clinical realization.
  • Continued research and development are vital for advancing gene therapy in cardiology.